ESPE Abstracts (2021) 94 P2-280

ESPE2021 ePoster Category 2 Growth and syndromes (to include Turner syndrome) (56 abstracts)

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status

Alexander AL Jorge 1 , Alberto Pietropoli 2 , Nicky Kelepouris 3 & Reiko Horikawa 4


1Unidade de Endocrinologia-Genetica, LIM/25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil; 2Novo Nordisk Health Care AG, Zürich, Switzerland; 3Novo Nordisk Inc., Plainsboro, NJ, USA; 4National Center for Child Health and Development, Tokyo, Japan


Objectives: Mutations in PTPN11 are known to be associated with Noonan syndrome (NS), accounting for approximately 50% of cases. Data from a non-interventional and phase 3 study of Norditropin (somatropin; Novo Nordisk A/S, Denmark) were used to assess the impact of PTPN11 mutation status on growth outcomes in children with NS receiving growth hormone therapy (GHT).

Methods: The ANSWER (NCT01009905) programme is a non-interventional, multicentre, observational study conducted in the United States; GHLIQUID-4020 (NCT01927861) is a 4-year, randomised, double-blind, multicentre trial in Japanese patients. In this analysis, data from patients in these studies with clinically diagnosed NS were pooled to assess the impact of PTPN11 mutation status on growth outcomes over 4 years of GHT. Data are presented for the subgroup of patients who were GHT-naïve and prepubertal at baseline.

Results: A total of 69 patients with known PTPN11 mutation status were included in the analysis: 49 tested positive for a mutation (PTPN11-positive) and 20 were PTPN11-negative; 47 were male and 22 were female. Gene mutations identified in PTPN11-negative patients included BRAF (n = 1), KRAS (n = 1), RAF1 (n = 3), RIT1 (n = 1), SHOC2 (n = 1) and SOS1 (n = 2). Cardiovascular comorbidities were present in 55% of patients at baseline, including atrial septal defect (n = 16; 23.2% of patients), pulmonary valve stenosis (n = 9; 13.0%), pulmonary artery stenosis (n = 7; 10.1%) and hypertrophic cardiomyopathy (n = 7; 10.1%). Baseline characteristics were generally similar between PTPN11-positive and negative patients. Mean (standard deviation [SD]) age at GHT start was 6.4 (3.3) years in PTPN11-positive and 6.4 (2.5) years in PTPN11-negative patients. Mean (SD) GHT dose at baseline was 0.047 (0.015) mg/kg/day in PTPN11-positive patients and 0.054 (0.016) mg/kg/day in PTPN11-negative patients. Change from baseline in height SD score (SDS) is shown in Table 1; no significant differences between PTPN11-positive and PTPN11-negative patients were observed.

Table 1. Change from baseline in height SDS
PTPN11-positivePTPN11-negative
YearNMeanSDNMeanSD
Height SDS (general population)Change from baseline1410.7420.364190.7550.407
2381.0860.531191.2010.562
3321.2720.685191.3990.624
4301.2580.839191.4880.743
Height SDS (Noonan population)Change from baseline1400.7190.352190.7110.363
2381.0580.565191.1610.492
3321.2920.695191.4120.550
4301.3700.759191.5220.651

Conclusions: GHT over 4 years resulted in improved growth outcomes in GHT-naïve, prepubertal NS patients, irrespective of PTPN11 mutation status.

Volume 94

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.